|CD303||CLEC4C (C-type lectin domain family 4, member C), CLECSF7, CLECSF11, BDCA2, DLEC, HECL|
|Molecule Type||Antigen Expression||Molecular Weight|
Min / Max
|Non-lineage Restricted Molecule|
Type 2 glycoprotein
|38 / 38|
|CD303 is expressed on plasmacytoid dendritic cell subsets, costitutively on immature monocyte-derived dendritic cells and significantly down-regulated upon maturation with LPS but not with TNF-α. Expression is in mature neutrophils and macrophages.|
|MOLECULAR FAMILY NAME: Belongs to the C-type lectin superfamily.|
CD303 is a single-pass type-2 183 aa glycoprotein. It contains a 23 aa signal anchor, an 169 aa extracellular domain which contains a C-type lectin domain and 3 potential N-glycosylation sites, a 23 aa transmembrane domain and a 21 aa N-terminal cytoplasmic domain but has no knwon signaling ITIM motifs.
Alterative splicing yields 2 different isoforms.
CD303 has 3 potential N-linked glycoslation sites.
|LIGANDS AND MOLECULE ASSOCIATED WITH CD303: No information.|
|CD303 is a C-type lectin of plasmacytoid dendritic cells. Members of this C-type lectin family share a common protein fold and have diverse functions, such as cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response and may play a role in dendritic cell function. In vitro studies have found that CD303 has a dual function of both capturing and targeting antigen for processing and peptide loading compartments for presentation to T cells and may mediate potent inhibitation of induction of IFN-α/β production and expression in plasmacytoid dendritic cells. Triggering of CD303 with mAb may act as a signaling receptor that activates protein in tyrosine kinases and mobilizes intracellular calcium but it does not seem to bind mannose. But in the absence of any known cytoplasmic signaqling motifs, it remains to be determined whether CD303 interacts interacts with a signaling membrane adaptor molecule.|
BIOCHEMICAL ACTIVITY: No information.
DISEASE RELEVANCE AND FUNCTION OF CD303 IN INTACT ANIMAL
CD303 is a specific marker and a potential therapeutic target for the down-regulation of IFNα/β production in patients with systemic lupus erthematosus (SLE).
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD303: No information.
SUBSTRATES: No information.
ENZYMES WHICH MODIFY CD303: No information.
For further information see Dzionek, A. et al (2001) J. Exp. Med. 194: 1823-1834.
Database accession numbers
Revised June 25, 2008